What We Do
Byondis is at the forefront of antibody-drug conjugate (ADC) innovation. Our highly experienced team is developing proprietary first-in-class technology that specifically tackles shortcomings and gaps of current ADC therapeutics.
Pipeline
Our diverse pipeline of proprietary next-generation ADCs reflects our expertise in research, lead identification, preclinical/clinical development, process development and manufacturing.
Platforms
Our antibody drug conjugate (ADC) technology platforms are generating potential first and best in class assets, including novel proprietary payloads, linker and drug conjugation and improved targeting. This includes clinically validated MOAs, dual payloads, tumor and site-specific release, optimized antibody scaffolds and increased tumor selectivity. These platforms are enabling us to forge a new pathway in ADC development and oncology treatment.
Key Technologies
Byondis has a suite of proprietary technologies available to generate promising clinical candidates. This includes next generation ADCs containing our proprietary duocarmazine linker-drug (LD) technology ByonZine®.
Publications & Presentations
Novel developments are regularly published in highly ranked peer-reviewed journals.
Who We Are
At Byondis, we are dedicated to transforming the lives of those affected by cancer.
Research & Development
Our programs target intractable cancers and autoimmune diseases, with the aim of creating innovative, safe and effective targeted medicines, based on new biological and new chemical entities.
